Epilepsy News and Research RSS Feed - Epilepsy News and Research Twitter

Epilepsy is a group of disorders marked by problems in the normal functioning of the brain. These problems can produce seizures, unusual body movements, a loss of consciousness or changes in consciousness, as well as mental problems or problems with the senses.
Young adults participated in cardio fitness activities may preserve memory, thinking skills in middle age

Young adults participated in cardio fitness activities may preserve memory, thinking skills in middle age

Young adults who run or participate in other cardio fitness activities may preserve their memory and thinking skills in middle age, according to a new study published in the April 2, 2014, online issue of Neurology®, the medical journal of the American Academy of Neurology. Middle age was defined as ages 43 to 55. [More]
Scientists present protein that facilitates control of nerve cells by light

Scientists present protein that facilitates control of nerve cells by light

​Networked nerve cells are the control center of organisms. In a nematode, 300 nerve cells are sufficient to initiate complex behavior. To understand the properties of the networks, re-searchers switch cells on and off with light and observe the resulting behavior of the organism. [More]
NeuroSigma gets approval to market Monarch eTNS System in Australia

NeuroSigma gets approval to market Monarch eTNS System in Australia

NeuroSigma, Inc., a California-based life-sciences company focused on commercialization of its non-invasive Monarch eTNS System for the treatment of neurological and neuropsychiatric disorders, today announced that it has received approval from the Therapeutic Goods Administration to market its Monarch eTNS System in Australia. [More]

Patients with autoimmune disease have 3.8-fold increased risk of developing epilepsy

Patients with an autoimmune disease have a 3.8-fold increased risk of developing epilepsy, according to a new population-level study from Boston Children's Hospital based on health insurance claim data. [More]
Otsuka acquires rights to develop and sell Eisai’s DACOGEN in the US, Canada and Japan

Otsuka acquires rights to develop and sell Eisai’s DACOGEN in the US, Canada and Japan

Eisai Inc., a subsidiary of Tokyo-based Eisai Co., Ltd., today announced the sale and assignment of its rights to a worldwide exclusive license for DACOGEN® (decitabine) for Injection to Otsuka Pharmaceutical Co., Ltd., giving Otsuka full development and commercialization rights for the product in the former Eisai territories of the United States, Canada and Japan. [More]

Researchers estimate psychosis rates in epilepsy

Patients with epilepsy are nearly eight times more likely than people without the condition to experience psychosis, show results of a systematic review and meta-analysis. [More]
People who develop diabetes in middle age are more likely to have brain cell loss in old age

People who develop diabetes in middle age are more likely to have brain cell loss in old age

People who develop diabetes and high blood pressure in middle age are more likely to have brain cell loss and other damage to the brain, as well as problems with memory and thinking skills, than people who never have diabetes or high blood pressure or who develop it in old age, according to a new study published in the March 19, 2014, online issue of Neurology®, the medical journal of the American Academy of Neurology. [More]

Bipolar disorder and epilepsy could be linked

A preliminary study adds to evidence that bipolar disorder and epilepsy may be different expressions of common pathways. [More]
Sea lions exposed to toxin in algae develop form of epilepsy that is similar to humans

Sea lions exposed to toxin in algae develop form of epilepsy that is similar to humans

California sea lions exposed to a toxin in algae develop a form of epilepsy that is similar to one in humans, according to a new study led by Stanford University School of Medicine researchers. [More]

CorTechs secures new Series B financing

Medical software developer CorTechs Labs, Inc. is pleased to announce it has secured new Series B financing to support the company's rapid growth. The round was led by Genting Berhad via its indirect wholly-owned subsidiary, Dragasac Limited, a company incorporated in the Isle of Man. [More]

Researchers discover USP9X gene that sheds new light on mysteries of brain development, disability

Research from the University of Adelaide has confirmed that a gene linked to intellectual disability is critical to the earliest stages of the development of human brains. [More]

Researcher detects higher rate of seizures among children with autism who were fed soy formula

A University of Wisconsin-Madison researcher has detected a higher rate of seizures among children with autism who were fed infant formula containing soy protein rather than milk protein. [More]

Children with ASD and ADHD are more likely to exhibit gender variance

John F. Strang, PsyD, a pediatric neuropsychologist at Children's National Health System, and colleagues, found that children with autism spectrum disorders (ASD) or attention deficit hyperactivity disorder (ADHD) were more likely to exhibit gender variance, the wish to be the other gender, than children with no neurodevelopmental disorder, or a medical neurodevelopmental disorder such as epilepsy or neurofibromatosis. [More]

Knopp and NIAID collaborate to investigate eosinophil-lowering effects of dexpramipexole

Knopp Biosciences LLC today announced a second collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to investigate the eosinophil-lowering effects of the investigational drug dexpramipexole. [More]
People with prehypertension more likely to develop stroke

People with prehypertension more likely to develop stroke

Anyone with blood pressure that's higher than the optimal 120/80 mmHg may be more likely to have a stroke, according to a new meta-analysis published in the March 12, 2014, online issue of Neurology, the medical journal of the American Academy of Neurology. [More]
Teenagers with autism spectrum disorder are more likely to wish to be another gender

Teenagers with autism spectrum disorder are more likely to wish to be another gender

Children and teenagers with an autism spectrum disorder or those who have attention deficit and hyperactivity problems are much more likely to wish to be another gender. [More]
Three innovative tools to detect, test and initiate personalized drug treatment for seizures

Three innovative tools to detect, test and initiate personalized drug treatment for seizures

A team of researchers from the National Institutes of Health, Emory University and Cedars-Sinai - specialists in identifying and treating very rare diseases - used three innovative tools to detect a previously unknown gene mutation, test potential therapies in the lab, and initiate personalized drug treatment for a boy with a lifelong history of uncontrollable seizures that caused significant impact on his cognitive and social development. [More]

Damage to brain cells plays role in development of epilepsy after traumatic brain injury

Traumatic brain injury is a risk factor for epilepsy, though the relationship is not understood. A new study in mice, published in Cerebral Cortex, identifies increased levels of a specific neurotransmitter as a contributing factor connecting traumatic brain injury (TBI) to post-traumatic epilepsy. The findings suggest that damage to brain cells called interneurons disrupts neurotransmitter levels and plays a role in the development of epilepsy after a traumatic brain injury. [More]

Genetic basis of hereditary disease causes severe brain atrophy in Jews of Moroccan ancestry

Ben-Gurion University of the Negev (BGU) researchers have unraveled the genetic basis of a hereditary disease that causes severe brain atrophy, mental retardation and epilepsy in Jews of Moroccan ancestry, according to a study published this week online in the Journal of Medical Genetics. [More]
FDA accepts Lundbeck's carbamazepine NDA for review

FDA accepts Lundbeck's carbamazepine NDA for review

Lundbeck LLC today announced that the U.S. Food and Drug Administration has accepted for review a New Drug Application (NDA) for its investigational therapy intravenous carbamazepine, an intravenous formulation of the anti-epileptic drug (AED) carbamazepine. An action letter is anticipated before the end of 2014. Carbella is the proposed U.S. trade name for intravenous carbamazepine. [More]